Uncertainty Regarding Anticoagulation After Intracerebral Hemorrhage in Patients with Atrial Fibrillation

Ischemic events were lower with anticoagulation than without it, but rates of death or dependency did not differ.

The use of direct oral anticoagulants (DOACs) is well established for patients with atrial fibrillation (AF) and elevated risk for stroke. However, for patients with AF and a recent intracerebral hemorrhage (ICH), whether use of DOACs has an overall benefit is unclear when considering the balance of ischemic and hemorrhagic events. These authors compiled individual patient data from four prospective studies that randomly assigned patients to either starting anticoagulation or avoiding anticoagulation. They performed a meta-analysis of these studies and evaluated the rate of any stroke or cardiovascular death during follow-up. Other endpoints of interest included ischemic cardiovascular events, major hemorrhage, and death or dependence at 1 …

Reviewing Author

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Uncertainty Regarding Anticoagulation After Intracerebral Hemorrhage in Patients with Atrial Fibrillation

Topics

Reviewing Author